Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.44 |
| ▸ | CXCR5 | P32302 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24287480 | 0.94 | LPAR1 (0.66) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| Fipaxalparant SCHEMBL29398637 | 0.91 | LPAR1 (0.78) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| Fipaxalparant SCHEMBL1560214 | 0.91 | LPAR1 (0.78) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| Fipaxalparant SCHEMBL29382253 | 0.91 | LPAR1 (0.78) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| SCHEMBL1560903 | 0.87 | LPAR1 (0.63) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| SCHEMBL1561222 | 0.87 | LPAR1 (0.65) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| SCHEMBL1561364 | 0.87 | LPAR1 (0.65) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| SCHEMBL1560188 | 0.87 | LPAR1 (0.65) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| SCHEMBL1561481 | 0.87 | LPAR1 (0.78) | LPAR1NPC1RAB9ASMPD1HDAC1 | |
| SCHEMBL24287489 | 0.87 | LPAR1 (0.57) | LPAR1SMPD1HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322657-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230322657-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2023-10-12 | — | — | US | disclosed |
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-21 | — | — | US | disclosed |
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-21 | — | — | US | disclosed |
| WO-2023166346-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-09-07 | — | — | WO | disclosed |
| WO-2022043755-A2 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2022-03-03 | — | — | WO | disclosed |
| US-20220064105-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | SANOFI (FR) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064105-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | EDNRA, EDNRB, FFAR2 | LPAR1 277/4885NPC1 1384/4885RAB9A 3469/4885 |
| US-20230322657-A1 | CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST AND METHODS OF MAKING | EDNRA, FFAR2, EDNRB | LPAR1 282/4885NPC1 1031/4885RAB9A 2805/4885 |
| US-20230295073-A1 | PROCESS OF MAKING A CRYSTALLINE EDG-2 RECEPTOR ANTAGONIST | EDNRA, EDNRB, FFAR2 | LPAR1 118/4885NPC1 2234/4885RAB9A 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.